This question presents a case of an 11-year-old girl with a history of recurrent chest infections, fever, productive cough, anorexia, weight loss, and failure to thrive. These symptoms are highly suggestive of cystic fibrosis, a genetic disorder that affects the lungs and digestive system. Patients with cystic fibrosis often have difficulty clearing mucus from their lungs, leading to recurrent infections.

Among the options provided, Pseudomonas is the most likely organism responsible for this presentation. Pseudomonas aeruginosa is a common pathogen in patients with cystic fibrosis and is known to cause respiratory infections in these individuals. It is particularly concerning as it can form biofilms in the airways, making it difficult to treat with antibiotics.

The other options, such as Pneumococcal pneumonia, Staphylococcus, Mycobacterium TB, and PCP, are less likely in this case given the patient’s history of recurrent infections and failure to thrive, which are more indicative of cystic fibrosis. Therefore, the correct answer is Pseudomonas.

Diagnosis and Management of HIV Nephropathy

HIV infection is a high possibility in a patient with risk factors and presenting with emaciation, oral ulcers, and lymphopenia. A CD4 count and HIV serological testing should be done urgently. HIV nephropathy is a common complication, with focal and segmental glomerulosclerosis being the most common pathological diagnosis. Other variants include membranoproliferative nephropathy, diffuse proliferative glomerulonephritis, minimal change disease, and IgA nephropathy. Treatment involves ACE inhibitors and antiretroviral therapy, with dialysis being necessary in end-stage disease. Renal biopsy is required to confirm the diagnosis, but HIV testing should be performed first. Serum IgA levels are elevated in IgA nephropathy, while serum complement levels and anti-nuclear factor are needed in SLE-associated nephropathy or other connective tissue diseases or vasculitis. However, the lack of systemic symptoms points away from these diagnoses.

Common Antibiotics for Chlamydia Treatment: Dosage and Suitability

Chlamydia is a sexually transmitted infection caused by the bacterium Chlamydia trachomatis. Antibiotics are the primary treatment for chlamydial infection. However, not all antibiotics are suitable for treating this infection. Here are some common antibiotics used for chlamydia treatment, their recommended dosage, and their suitability for this infection.

Doxycycline 100 mg 12 hourly for 7 days
This is the recommended treatment for Chlamydia in adults/children over 13 years, according to National Institute for Health and Care Excellence (NICE) guidelines and British Association for Sexual Health and HIV (BASHH) guidance.

Doxycycline 100 mg 12-hourly for 3 days
Even though doxycycline is used to treat infection with Chlamydia, a course of 100 mg 12-hourly over 3 days is not sufficient. Doxycycline 100 mg 12-hourly for 7 days is the recommended course.

Amoxicillin 500 mg every 8 hours for 7 days
Amoxicillin targets Gram-positive bacteria and is hence an unsuitable antibiotic for chlamydial infection.

Azithromycin 3 g orally single dose
A dose of 3 g per day is much too high. The recommended dose for azithromycin to treat chlamydial infection is 1 g orally per day.

Clarithromycin 250 mg for 14 days
Clarithromycin is not typically used to treat infection with C. trachomatis. It is most commonly used to treat respiratory tract infections, soft tissue infections and as part of the treatment for H. pylori eradication.

Urinary tract infections (UTIs) are a common health issue, especially among women. The most common causative agent of UTIs in females is Escherichia Coli, also known as E. Coli. E. Coli is a type of bacteria that is commonly found in the environment and in the gastrointestinal system of humans.

E. Coli is able to cause UTIs in females by entering the urinary tract through the urethra and multiplying in the bladder. This can lead to inflammation and infection of the urinary tract, resulting in symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.

While E. Coli is the most common causative agent of UTIs in females, other bacteria such as Klebsiella species, Proteus species, and various Enterococci can also cause UTIs. It is important for individuals experiencing symptoms of a UTI to seek medical attention and receive appropriate treatment, which usually involves antibiotics to clear the infection. Additionally, practicing good hygiene, staying hydrated, and urinating after sexual intercourse can help prevent UTIs.

Hepatorenal syndrome is a serious complication of liver cirrhosis that can lead to kidney failure. In patients with spontaneous bacterial peritonitis, the risk of developing hepatorenal syndrome is increased. In this case, the best treatment option to prevent the patient from developing hepatorenal syndrome is intravenous albumin administration.

Albumin has been shown in randomized controlled trials to have a positive effect on circulatory systems, which can help prevent the development of hepatorenal syndrome. Central venous pressure monitoring can help assess the patient’s fluid status, but in this case, the patient does not have symptoms of hypovolaemia. Intravenous dopamine infusion is not indicated for the prevention of hepatorenal syndrome.

Regular lactulose use is primarily used for the prevention of hepatic encephalopathy, which is not relevant in preventing hepatorenal syndrome. Neomycin, while sometimes used for hepatic encephalopathy, is associated with nephrotoxicity and ototoxicity and is not recommended for preventing hepatorenal syndrome.

Therefore, in this case, the best treatment option to prevent the patient from developing hepatorenal syndrome is intravenous albumin administration.

Repeat viral load testing is an important aspect of monitoring HIV treatment effectiveness in clients. The range of viral load considered for clients with repeat testing helps healthcare providers determine the level of viral replication in the body and assess the response to antiretroviral therapy.

A viral load of < 10 c/mL is considered undetectable and indicates successful suppression of the virus. This is the ideal outcome for clients on HIV treatment. A viral load of 10-49 c/mL is still considered low and may not necessarily indicate treatment failure, but it does warrant closer monitoring. A viral load of 50-999 c/mL falls within the range of persistent low-grade viremia. This level of viral replication may indicate suboptimal adherence to treatment or the development of drug resistance. Clients in this range require careful monitoring and potential interventions to address any issues that may be affecting treatment efficacy. A viral load of ≥ 1000 c/mL is considered high and indicates treatment failure. This level of viral replication may lead to disease progression and the development of complications. Clients with a viral load in this range may need to switch to a different antiretroviral regimen to achieve viral suppression. Therefore, the correct answer to the question is 50-999 c/mL, as clients falling within this range on repeat viral load testing are categorized as having persistent low-grade viremia and require closer monitoring and potential interventions to optimize treatment adherence and efficacy.

Clostridium infection is best described as being caused by anaerobic Gram-positive bacilli. Clostridium bacteria are anaerobes, meaning they thrive in environments without oxygen. They are also Gram-positive, which means they have a thick cell wall that retains a violet dye during the Gram staining process. Clostridium bacteria are typically rod-shaped and are capable of forming endospores, which are resistant structures that allow them to survive in harsh conditions. Some important human pathogens within the Clostridium genus include Clostridium botulinum, which causes botulism, and Clostridium difficile, a common cause of diarrhea.

Zidovudine (AZT) is a medication commonly used to prevent mother-to-child transmission of HIV. In infants aged birth to 6 weeks and weighing between 2.0 to 2.49 kg, the recommended dose of Zidovudine is 1.5 ml (15 mg) twice daily. This dosage is based on the weight of the infant and is important to ensure the medication is effective and safe for the child.

The patient has sickle cell disease and a history of recurrent infections, indicating long-term damage to the spleen. The blood film shows signs of splenic disruption, such as Howell-Jolly bodies, and a low lymphocyte level, which may be due to reduced lymphocyte storage capacity in the shrunken spleen. This is different from a splenic sequestration crisis, which is an acute pediatric emergency. The current admission may be an acute chest pain crisis, but it is not the cause of the recurrent infections. The patient does not have acute lymphoblastic leukemia, as there is no evidence of blastic cells or pancytopenia. Advanced HIV is a possibility, but the blood film suggests sickle cell disease. While the patient is at risk of an aplastic crisis, it typically occurs in younger patients after a parvovirus B19 infection, which is not present in this case.

Aminoglycosides work on the Ribosome 30 S to prevent Protein synthesis, while Chloramphenicol works on Ribosome 50 S peptidyl transferase. Aminoglycosides are bactericidal and have good activity against Gram-negative aerobes and some anaerobic bacilli. On the other hand, Chloramphenicol is bacteriostatic and inhibits protein synthesis by preventing protein chain elongation through inhibition of the peptidyl transferase activity of the bacterial ribosome. Therefore, the correct statement is that Aminoglycosides work on Ribosome 30 S to prevent Protein synthesis.

Resistance testing is crucial in clients failing a first-line antiretroviral therapy (ART) regimen because it helps clinicians understand why the current treatment is not working effectively. By identifying mutations associated with drug resistance, healthcare providers can make informed decisions about switching to a different combination of antiretroviral drugs that will be more effective in suppressing the virus.

Confirming the diagnosis of HIV, determining the patient’s CD4 count, assessing liver function, and monitoring for signs of lipodystrophy are all important aspects of managing HIV infection, but they are not the primary goal of resistance testing in clients failing a first-line ART regimen. The main focus of resistance testing in this context is to identify mutations that are causing the treatment to fail, so that appropriate adjustments can be made to improve the patient’s response to therapy.

Benzathine penicillin G is a type of antibiotic that is commonly used to treat bacterial infections. One of the common side effects of this medication is injection site pain and swelling. This occurs because the medication is administered via injection, which can cause discomfort and inflammation at the site of injection.

Nausea and vomiting, rash and itching, renal failure, and anaphylaxis are also potential side effects of Benzathine penicillin G administration, but they are less common than injection site pain and swelling. Nausea and vomiting may occur due to the medication’s effects on the gastrointestinal system, while rash and itching may be a sign of an allergic reaction. Renal failure is a rare but serious side effect that can occur in some individuals. Anaphylaxis is a severe allergic reaction that can be life-threatening and requires immediate medical attention.

Overall, it is important to be aware of the potential side effects of Benzathine penicillin G and to seek medical help if any concerning symptoms occur after administration.

For clients on ART with a viral load (VL) ≥ 1000 c/mL and adherence over 80%, the guidelines recommend focusing on improved adherence before considering any changes to the regimen. The rationale is that resistance to Dolutegravir (DTG), a common component in ART regimens, is very uncommon, so addressing adherence issues is crucial for achieving viral suppression.

Prevalence in epidemiology refers to the proportion of a population that has a specific condition at a given point in time. This can be expressed as a fraction, percentage, or number of cases per 10,000 or 100,000 people. Point prevalence specifically looks at the proportion of the population with the condition at a specific point in time, while period prevalence considers the proportion of the population that has the condition at some point during a given period.

Lifetime prevalence, on the other hand, looks at the proportion of the population that has experienced the condition at some point in their life up to the time of assessment. This includes individuals who may have had the condition in the past but no longer have it.

In the context of infectious diseases, prevalence can help public health officials understand the burden of a disease within a population and inform strategies for prevention and control. Sero-prevalence and seroconversion specifically refer to the prevalence of antibodies in a population and the rate at which individuals develop antibodies, respectively.

Overall, prevalence is an important measure in epidemiology that provides valuable information about the distribution of diseases and risk factors within a population.

Trimethoprim is an antibiotic that works by inhibiting the bacterial enzyme dihydrofolate reductase. This enzyme is essential for the reduction of dihydrofolic acid (DHF) to tetrahydrofolic acid (THF), which is a crucial precursor in the synthesis of thymidine, a component of DNA. By blocking this enzyme, Trimethoprim disrupts the production of THF, leading to a decrease in DNA synthesis and ultimately inhibiting bacterial growth. Therefore, the correct mechanism of action for Trimethoprim is to inhibit Folic Acid metabolism.

The first viral load (VL) test after initiating antiretroviral therapy (ART) is crucial in monitoring the effectiveness of the treatment and ensuring viral suppression. By conducting the VL test after 3 dispensing cycles, healthcare providers can assess how well the ART regimen is working and if the patient is achieving the desired viral suppression levels.

Testing after 3 dispensing cycles allows for enough time for the medication to take effect and for the patient’s viral load to stabilize. This timing also aligns with the typical follow-up schedule for patients starting ART, making it a convenient and practical time to conduct the test.

Early detection of any issues affecting viral suppression is key to optimizing treatment outcomes and preventing the development of drug resistance. By monitoring the viral load early on in the treatment process, healthcare providers can make necessary adjustments to the ART regimen or provide additional support to help the patient achieve and maintain viral suppression.

Overall, conducting the first VL test after 3 dispensing cycles is a recommended practice in the 2023 ART Clinical Guidelines to ensure effective monitoring of treatment progress and improve outcomes for individuals living with HIV.

The patient has Kaposi’s sarcoma, which is caused by human herpesvirus 8. This condition can be the first presentation of AIDS in some HIV patients and is more common in males and men who have sex with men. The skin lesions appear as red-purple papules or plaques and can also be found on mucous membranes. Kaposi’s sarcoma mainly affects the skin, but it can also affect the lungs and gastrointestinal tract. Symptoms of pulmonary Kaposi’s sarcoma include cough, shortness of breath, and haemoptysis, while gastrointestinal involvement can cause intestinal obstruction.

CMV infection can occur as reactivation or primary infection, usually in those with low CD4+ counts. In the immunocompromised, it can present with chorioretinitis, encephalitis, pneumonitis, or gastrointestinal disease. HPV is a common virus that causes genital warts, verrucas, and warts on the lips/oral mucosa. It is also a major risk factor for cervical and anal cancers. In immunosuppressed patients, the severity of HPV symptoms and risk of cancer are increased. HSV 1 and 2 are common viruses that can cause oral and genital herpes. In immunosuppression, these viruses may reactivate more frequently and cause more severe symptoms. Cryptococcus neoformans is a fungus that can cause opportunistic infections in AIDS, mostly causing fungal pneumonia and subacute meningitis, but it does not typically cause skin lesions.

Persistent watery diarrhea in a patient with HIV is most likely caused by Cryptosporidium. Cryptosporidium is a parasite that can cause infection and diarrhea in immunocompromised individuals, such as those with HIV. In immunocompetent individuals, this organism typically does not cause symptoms. However, in those with HIV, particularly those with low CD4 counts, Cryptosporidium can lead to prolonged, severe, or extraintestinal infection.

Other potential causes of persistent watery diarrhea in patients with HIV include Salmonella infection, colorectal cancer, and side effects of HAART therapy. However, in the context of HIV and diarrhea, Cryptosporidium should be the top consideration. It is important to consider the patient’s immune status and CD4 count when evaluating the cause of persistent diarrhea in HIV patients.

All of the organisms listed above can cause pneumonia in immunocompromised individuals but the most likely cause in this patient is Pneumocystis jirovecii.

It is a leading AIDS-defining infection in HIV-infected individuals and causes opportunistic infection in immunocompromised individuals. HIV patients with a CD4 count less than 200 cells/mm3 are more prone.

The clinical features of pneumonia caused by Pneumocystis jirovecii are:
Fever, chest pain, cough (usually non-productive), exertional dyspnoea, tachypnoea, crackles and wheeze.
Desaturation on exertion is a very sensitive sign of Pneumocystis jirovecii pneumonia.

Chest X-ray can show perihilar fluffy shadowing (as is seen in this case) but can also be normal.

This question presents a case of an 8-week-old infant diagnosed with HIV, born to a mother with HIV. The infant had received some antiretroviral prophylaxis after birth, but ultimately tested positive for HIV. The initial laboratory studies show a high HIV RNA level and normal CD4 count. The question asks for the most appropriate management for the infant.

The correct answer is to initiate antiretroviral therapy urgently. This is based on the Pediatric ART Guidelines, which recommend urgent initiation of antiretroviral therapy for all infants younger than 12 months of age with confirmed HIV infection, regardless of clinical status, CD4 count, or CD4 percentage. Early initiation of antiretroviral therapy has been shown to significantly reduce the risk of HIV-related morbidity and mortality in infants with HIV.

It is important to note that antiretroviral therapy should not be delayed while waiting for results from HIV drug resistance testing. The regimen can be adjusted later based on the results of the drug resistance testing. The urgency in starting treatment is crucial in order to provide the best possible outcome for the infant.

According to the CDC definition, a patient co-infected with HIV can be diagnosed with AIDS if he or she has:
A CD4 T-cell count of less than 200 cells/mm3 or;
A CD4 T-cell percentage of total lymphocytes of less than 15% or;
An AIDS defining infection

A Streptococcal throat infection is not an AIDS defining infection.

A normal CD4 count ranges from 500-1000 cells/mm3. A CD4 (not CD8) count of less than 200 cells/mm3 is AIDS defining.

The CD4 count can vary from day to day and depending upon the time that the blood test is taken. It can also be affected by the presence of other infections or illnesses. Treatment with antiretroviral therapy should be considered at CD4 count of less than 350 cells/mm3.

Serum concentrations of the p24 antigen (the viral protein that makes up most of the core of the HIV) are usually high in the first few weeks after human immunodeficiency virus (HIV) infection and testing for p24 antigen is therefore a useful way of diagnosing very early infection.

Infants born to mothers with a high viral load of ≥ 1000 c/ml at delivery are at a higher risk of contracting HIV during childbirth. Therefore, it is recommended to provide these infants with a more aggressive prophylaxis regimen to reduce the risk of HIV transmission.

The recommended prophylaxis for infants born to mothers with a viral load ≥ 1000 c/ml at delivery or with no viral load available is AZT (zidovudine) twice daily for six weeks and NVP (nevirapine) daily for a minimum of 12 weeks. This combination of medications helps to reduce the risk of HIV transmission from mother to child by suppressing the virus in the infant’s system.

It is important to follow the recommended prophylaxis regimen to ensure the best possible outcome for the infant and reduce the risk of HIV transmission. Regular monitoring and follow-up care are also essential to ensure the infant’s health and well-being.

PrePex Device Offers Painless Male Circumcision for HIV Prevention

The PrePex device is a new method of male circumcision that is painless, sutureless, and does not require anaesthesia. It has been approved in countries such as Rwanda and is currently only available in sub-Saharan Africa. The World Health Organization (WHO) has found scientific evidence that male circumcision can significantly reduce the risk of HIV transmission. As a result, WHO is promoting this strategy in sub-Saharan Africa, where there has been a significant increase in the number of circumcision operations. However, it is important to note that circumcision should be used in conjunction with other measures, such as condom use, to reduce the incidence of HIV infection. The PrePex device is not designed for any other purposes.

Gram positive rods are a type of bacteria that have a thick peptidoglycan layer in their cell wall, which retains the crystal violet stain in the Gram staining process, giving them a purple color under a microscope. Some examples of Gram positive rods include bacteria from the Clostridium genus, which includes species like Clostridium botulinum and Clostridium tetani.

Gram positive bacilli are another type of bacteria that are rod-shaped and stain purple in the Gram staining process. Examples of Gram positive bacilli include bacteria from the Bacillus genus, such as Bacillus anthracis, and the Clostridium genus, such as Clostridium perfringens.

Gram negative bacilli are a type of bacteria that have a thinner peptidoglycan layer in their cell wall, which does not retain the crystal violet stain in the Gram staining process, causing them to appear pink under a microscope. Examples of Gram negative bacilli include bacteria from the Enterobacter genus, such as Enterobacter cloacae, and the Pseudomonas genus, such as Pseudomonas aeruginosa.

Examples of Gram positive bacilli:
Bacillus genus
Clostridium genus
Corynebacterium genus
Listeria genus
Propionibacterium genus

Examples of Gram negative bacilli:
Bacteroides genus
Citrobacter genus
Enterobacter genus
Escherichia genus
Pseudomonas genus
Proteus genus
Salmonella genus
Serratia genus
Shigella genus
Yersinia genus

The primary concern regarding the use of dolutegravir (DTG) in pregnant women is the increased risk of neural tube defects (NTDs). NTDs are birth defects that occur when the neural tube, which forms the brain and spinal cord, fails to close properly during early pregnancy. Studies have shown that DTG may increase the risk of NTDs if used in the first four weeks after conception. Therefore, caution is advised when prescribing DTG to pregnant women, and alternative antiretroviral medications may be considered to reduce this risk. It is important for healthcare providers to carefully weigh the potential benefits and risks of DTG in pregnant women to ensure the best possible outcomes for both the mother and the baby.

Tuberculosis is a chronic infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs but can also involve other organs, including lymph nodes. In cases of tuberculous lymphadenopathy, the lymph nodes become enlarged and may form granulomas, which are collections of immune cells that form in response to the infection.

Caseation necrosis is the histopathologic feature most likely consistent with the diagnosis of tuberculosis. Caseation necrosis is a type of necrosis characterized by a cheese-like appearance due to the presence of lipid-laden macrophages. This type of necrosis is commonly seen in tuberculosis infections and is a key feature in the diagnosis of the disease.

Liquefactive necrosis, on the other hand, is a type of necrosis characterized by the formation of a liquid-filled cavity in the tissue. This type of necrosis is not typically associated with tuberculosis.

The presence of fibroblasts, Gram positive cocci, and neutrophils are not specific features of tuberculosis and are not typically seen in cases of tuberculous lymphadenopathy.

In summary, the presence of caseation necrosis in granulomas is a key histopathologic feature that is consistent with the diagnosis of tuberculosis.

Live attenuated vaccines are vaccines that contain a weakened form of the virus itself. They have the advantage of being able to provide a strong immune response, but they also come with potential risks. One concern is the possibility of the weakened virus reverting back to a more virulent strain. Additionally, live vaccines are easily damaged by heat and light, so they must be stored and refrigerated carefully.

One side effect of live attenuated vaccines can be egg hypersensitivity, particularly in vaccines like the Measles-Mumps-Rubella (MMR) vaccine which is produced using eggs. Another potential side effect is toxicity, as the weakened virus in the vaccine could potentially cause harm.

Live attenuated vaccines may also require booster shots to maintain immunity, as the immune response may not be as long-lasting as with other types of vaccines. These vaccines are not recommended for immunocompromised individuals, as they could potentially cause harm in those with weakened immune systems.

Overall, live attenuated vaccines have both advantages and disadvantages, and it is important to weigh the risks and benefits when considering vaccination options.

In the UK, TB screening for high-risk patients, such as migrants from Eastern Europe, is important to detect and prevent the spread of tuberculosis. One true statement concerning TB screening in the UK is that vaccination with the BCG can result in a false positive test. This is because the BCG vaccine can cause a reaction in the Mantoux test, leading to a false positive result.

The Mantoux test involves the injection of 5 Tuberculin units (0.1mL) intradermally and the result is read 2-3 days later. This test replaced the Heaf test as the TB screening test in the UK in 2005. The ‘Sterneedle’ gun is used to inject 100,000 units/ml of tuberculin purified protein derivative into the skin for the Heaf test, not the Mantoux test.

It is important to note that the interferon gamma release assay (IGRA) should not be used for neonates, as it is not as reliable in this age group. Overall, TB screening in the UK involves various tests and considerations to accurately detect and manage tuberculosis in high-risk individuals.

Steps to manage a patient in primary care:

• Confirm the Diagnosis:
  • HIV Testing: Ensure that the HIV diagnosis is confirmed through appropriate testing, typically with two different types of HIV tests to avoid false positives.
• Baseline Assessment:
  • Medical History and Physical Examination: Obtain a detailed medical history, including any symptoms, previous illnesses, and risk factors. Conduct a thorough physical examination.
  • Baseline Laboratory Tests: These should include:
    • CD4 Count: To assess the patient’s immune status.
    • Viral Load: To determine the level of HIV in the blood.
    • Complete Blood Count (CBC): To check for anemia, leukopenia, or thrombocytopenia.
    • Liver and Kidney Function Tests: To evaluate the patient’s overall health and potential contraindications for certain medications.
    • Screening for Opportunistic Infections: Tests for tuberculosis, hepatitis B and C, and sexually transmitted infections (STIs).
• Counseling and Education:
  • HIV Education: Provide the patient with information about HIV, its transmission, and the importance of adherence to antiretroviral therapy (ART).
  • Treatment Expectations: Discuss the benefits and potential side effects of ART.
  • Adherence Counseling: Emphasize the importance of taking ART consistently and the impact of adherence on treatment success.
  • Disclosure and Support: Offer counseling on the importance of disclosing their HIV status to sexual partners and provide support options.

Once these steps have been taken, one can start initiating treatment.

• Initiate Antiretroviral Therapy (ART):
  • Selection of ART Regimen: Follow the national guidelines (NDOH 2020 guidelines for treatment initiation), typically involving a combination of three antiretroviral drugs.
  • First-Line Regimen: Common first-line regimens in South Africa may include a combination of Tenofovir (TDF), Lamivudine (3TC), and Dolutegravir (DTG).

Pharmacovigilance is the practice of monitoring and assessing the safety and effectiveness of medications after they have been approved for use in the general population. The ultimate goal of pharmacovigilance is to improve patient care and public health by ensuring that medications are used safely and effectively. This involves identifying and evaluating potential risks and side effects associated with medications, as well as promoting the rational use of medicines to minimize harm and maximize benefits.

The answer To sell more medicines is incorrect because pharmacovigilance is not focused on increasing sales of medications, but rather on ensuring their safe and effective use. The answer To increase the cost of healthcare is also incorrect as pharmacovigilance aims to improve patient care and public health while minimizing unnecessary healthcare costs. The answer To promote specific medications is incorrect as pharmacovigilance is not about promoting specific medications, but rather about monitoring the safety and effectiveness of all medications. The answer To improve healthcare infrastructure is incorrect as pharmacovigilance is focused on monitoring medications, not infrastructure.